Expertise in
23
conditions

Thomas J. Vogl

Union Hospital, 
Wuhan, CN 
Expertise in
23
conditions
Union Hospital, 
Wuhan, CN 

Overview

Thomas Vogl practices practicing medicine in Wuhan, China.

Vogl is highly rated in 23 conditions, according to our data. Their clinical expertise encompasses Liver Cancer, Tonsillitis, Lung Metastases, Prostatic Artery Embolization, and Liver Embolization.

They are actively involved in clinical research, co-authoring 938 peer reviewed articles and participating in 6 clinical trials.

Locations

Union Hospital, Wuhan, 430022, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

The CArdiac Imaging RegistrY Study: Computed ToMogrAphy for Risk Stratification and Diagnostic Safety
The CArdiac Imaging RegistrY Study: Computed ToMogrAphy for Risk Stratification and Diagnostic Safety
Enrollment Status: Completed
Publish Date: January 06, 2026
A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Drug
Study Phase: Phase 3
An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: October 17, 2022
Intervention Type: Device, Drug
Study Phase: Phase 2
To Evaluate the Safety & Palliative Treatment Effect on Patients With Solid Cancers by Immunostimulating Interstitial Laser Thermotherapy (imILT)
To Evaluate the Safety & Palliative Treatment Effect on Patients With Solid Cancers by Immunostimulating Interstitial Laser Thermotherapy (imILT)
Enrollment Status: Terminated
Publish Date: January 30, 2019
Intervention Type: Device
Study Phase: Not Applicable
The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)
The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)
Enrollment Status: Completed
Publish Date: May 07, 2018
Intervention Type: Device, Procedure
Study Phase: Not Applicable
A Prospective, Multicenter Clinical Study to Evaluate the Clinical Outcomes of Targeted Radiofrequency Ablation and Vertebral Augmentation to Treat Painful Metastatic Vertebral Body Tumor(s)
A Prospective, Multicenter Clinical Study to Evaluate the Clinical Outcomes of Targeted Radiofrequency Ablation and Vertebral Augmentation to Treat Painful Metastatic Vertebral Body Tumor(s)
Enrollment Status: Terminated
Publish Date: January 20, 2017
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials

938 Total Publications

Effects of Postinterventional Antithrombotic Use on Transjugular Intrahepatic Portosystemic Shunts: Evaluation of DeGIR Registry Data (Germany, 2021-2024).
Effects of Postinterventional Antithrombotic Use on Transjugular Intrahepatic Portosystemic Shunts: Evaluation of DeGIR Registry Data (Germany, 2021-2024).
Journal: RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
Published: August 26, 2026

Frequently Asked Questions about Thomas J. Vogl

Is Thomas J. Vogl a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Thomas J. Vogl is classified as an Distinguished expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Thomas J. Vogl participate in research or clinical trials?

Yes. Thomas J. Vogl has published 938 articles and abstracts on conditions like Liver Cancer. You can view a list of Thomas J. Vogl's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Vogl's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 130 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile